A new study published in the Journal of American Medical Association (JAMA) showed that tumor-treating field (TTF) devices help to improve overall survival and delayed tumor recurrence for glioblastoma patients.
The first TTF device, or Optune™, is manufactured by Novocure and was approved by the FDA on October 5, 2015 for the treatment of newly diagnosed glioblastoma patients. The TTF device is a cap worn over the head that emits low-intensity electric waves that have been shown to interrupt the cancer cell’s ability to divide, slowing the progression of the tumor or causing it to shrink, according to study investigators.
In a study of nearly 700 GBM patients, the TTF device was given to two-thirds of the patients after receiving standard cancer treatments and one-third received temozolomide alone. According to the study, led by University Hospital Zurich, people who received the TTF device remained “cancer-free” an average of three months longer than those who only received chemotherapy – approximately 7.1 months compared with four months.
To read more about this study, click here.